We further found that sorafenib treatment directly induced PD-L1 expression via ERK-mediated NF-kB activation in murine and human HCC cells in a dose dependent manner (at low doses), which was prevented by MEK or NF-kB inhibition (Figs 6a–c and S9). This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.